Literature DB >> 33067724

Health utility of type 2 diabetes patients using basal insulin in China: results from the BEYOND II study.

Chaoyun Li1, HuiJun Zhou2, Pei Wang3,4.   

Abstract

OBJECTIVE: To derive the health utility scores of type 2 diabetes (T2D) patients using basal insulin (BI) with diverse characteristics in China.
METHODS: The study used the data of insulin-using T2D patients on BI treatment enrolled in the BEYOND II study, which is a multi-center, observational study from 78 hospitals nationwide. The 3-level EQ-5D (EQ-5D-3L) questionnaire was administered to each patient to derive their health utility scores using the EQ-5D-3L value set for China. Patients' clinical and sociodemographic information were retrieved from their electronic case report form (eCRF). Ordinary least-square models with different specifications were explored to identify the best-fitting model to predict the utility scores.
RESULTS: The sample (n = 12,583) achieved a mean (standard deviation) EQ-5D-3L utility score of 0.936 (0.120). According to the model, a Chinese male who was younger than 59 years, not underweight, diagnosed with T2D shorter than 10 years, with controlled plasma glucose and free of diabetes complications/comorbidities, would have a mean utility of 0.993. Being female, older age, underweight, and higher plasma glucose, longer diabetes duration was negatively related to EQ-5D-3L scores. Comorbidities and seven of eleven complications were associated with utility decrement. Interactions between some complications were also discovered.
CONCLUSIONS: The derived health utility scores for diabetes complications could facilitate the assessment of the cost-effectiveness of health interventions for Chinese insulin-using T2D patients.

Entities:  

Keywords:  Complications; EQ-5D; Insulin; Type 2 diabetes; Utility

Mesh:

Substances:

Year:  2020        PMID: 33067724     DOI: 10.1007/s00592-020-01618-1

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  2 in total

1.  Cost-Effectiveness of Dipeptidylpeptidase-4 Inhibitors Added to Metformin in Patients With Type 2 Diabetes in China.

Authors:  Wen-Qiang Lin; Zhong-Jie Cai; Tingting Chen; Mao-Bai Liu; Na Li; Bin Zheng
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-13       Impact factor: 5.555

2.  Cost-Effectiveness Analysis of Dapagliflozin Plus Standard Treatment for Patients With Type 2 Diabetes and High Risk of Cardiovascular Disease in China.

Authors:  Kaiyu Huang; Yao Wang; Sijia Sun; Qian Zhu; Weifeng Zhou; Jiatao Liu; Dongchun Zhu; Xuefeng Xie
Journal:  Front Public Health       Date:  2022-07-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.